Dec 14

Artiva Named a PM360 2023 Innovative Startup

Artiva was recognized in the 2023 PM360 Innovations Issue for advancing the first allogeneic NK cell therapy to clinical trials for lupus nephritis. 

Artiva’s mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our large-scale manufacturing process is capable of producing thousands of doses of cryopreserved, infusion-ready AlloNK cells from a single umbilical cord blood unit.

Read more about this recognition here.

Recent Posts

See All

In Vivo: Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm

Artiva’s President and CEO Fred Aslan, M.D., explores how Artiva is reshaping cell therapy with In Vivo.  In the maturing landscape of cell therapy, Artiva Biotherapeutics stands out for its unique approach: using un-engineered natural killer (NK) cells for oncologic and immune indications. Read the full article here (subscription may be required).

Drug Discovery World: Expanding Access to Cell Therapies for Autoimmune Conditions

DDW Editor Reece Armstrong speaks to Fred Aslan, MD, President and Chief Executive Officer of Artiva Biotherapeutics, about how to scale-up access to cell and gene therapies for patients suffering from autoimmune diseases. The rise of cell therapies in the past decade has led to meaningful clinical responses across both haematological diseases like blood cancer,...

PharmaVoice: Natural Killer Cells, a Rising Alternative to CAR-T Cell Therapy

Natural killer cells continuously patrol the human body, swiftly eliminating viruses and cancer cells, like sharks in prey-laden waters. Several biotech companies are harnessing the power of these innate immune crusaders in oncology and autoimmune diseases, potentially positioning them as a strong competitor to CAR-T cell therapies. “The advantage of NK cells over a T-cell approach...